Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.38
STJ's Cash to Debt is ranked higher than
51% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. STJ: 0.38 )
STJ' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.38

Equity to Asset 0.38
STJ's Equity to Asset is ranked higher than
50% of the 373 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. STJ: 0.38 )
STJ' s 10-Year Equity to Asset Range
Min: 0.38   Max: 0.83
Current: 0.38

0.38
0.83
Interest Coverage 12.98
STJ's Interest Coverage is ranked higher than
55% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 81.00 vs. STJ: 12.98 )
STJ' s 10-Year Interest Coverage Range
Min: 7.08   Max: 9999.99
Current: 12.98

7.08
9999.99
F-Score: 4
Z-Score: 3.35
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.11
STJ's Operating margin (%) is ranked higher than
91% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. STJ: 19.11 )
STJ' s 10-Year Operating margin (%) Range
Min: 14.63   Max: 26.83
Current: 19.11

14.63
26.83
Net-margin (%) 13.14
STJ's Net-margin (%) is ranked higher than
89% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. STJ: 13.14 )
STJ' s 10-Year Net-margin (%) Range
Min: 2.17   Max: 17.89
Current: 13.14

2.17
17.89
ROE (%) 17.09
STJ's ROE (%) is ranked higher than
95% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 5.57 vs. STJ: 17.09 )
STJ' s 10-Year ROE (%) Range
Min: 3.05   Max: 23.39
Current: 17.09

3.05
23.39
ROA (%) 7.06
STJ's ROA (%) is ranked higher than
85% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. STJ: 7.06 )
STJ' s 10-Year ROA (%) Range
Min: 1.56   Max: 14.16
Current: 7.06

1.56
14.16
ROC (Joel Greenblatt) (%) 39.98
STJ's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 12.89 vs. STJ: 39.98 )
STJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 18.88   Max: 59.77
Current: 39.98

18.88
59.77
Revenue Growth (%) 6.60
STJ's Revenue Growth (%) is ranked higher than
79% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. STJ: 6.60 )
STJ' s 10-Year Revenue Growth (%) Range
Min: -4.2   Max: 21
Current: 6.6

-4.2
21
EBITDA Growth (%) -4.60
STJ's EBITDA Growth (%) is ranked higher than
73% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -2.90 vs. STJ: -4.60 )
STJ' s 10-Year EBITDA Growth (%) Range
Min: -9.8   Max: 22.2
Current: -4.6

-9.8
22.2
EPS Growth (%) -3.30
STJ's EPS Growth (%) is ranked higher than
74% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. STJ: -3.30 )
STJ' s 10-Year EPS Growth (%) Range
Min: -37   Max: 120.5
Current: -3.3

-37
120.5
» STJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

STJ Guru Trades in Q3 2013

Paul Tudor Jones 4,200 sh (New)
Steven Cohen 273,744 sh (+1286.89%)
Bill Frels 2,119,012 sh (+8.95%)
James Barrow 3,062,827 sh (+8.78%)
Ken Fisher 309,565 sh (+1.83%)
John Buckingham 106,684 sh (+0.28%)
Steven Cohen 300,000 sh (unchged)
Jim Simons Sold Out
Pioneer Investments Sold Out
John Hussman Sold Out
Ray Dalio Sold Out
Jeremy Grantham 207,433 sh (-7.34%)
Mario Gabelli 74,618 sh (-12.22%)
John Rogers 1,573,176 sh (-12.4%)
Vanguard Health Care Fund 6,297,900 sh (-12.98%)
Joel Greenblatt 27,075 sh (-50.12%)
David Dreman 49,625 sh (-62.23%)
» More
Q4 2013

STJ Guru Trades in Q4 2013

John Hussman 350,000 sh (New)
Andreas Halvorsen 1,486,735 sh (New)
Paul Tudor Jones 11,101 sh (+164.31%)
Jeremy Grantham 224,404 sh (+8.18%)
John Buckingham 110,152 sh (+3.25%)
James Barrow 3,151,847 sh (+2.91%)
John Rogers 1,604,471 sh (+1.99%)
Vanguard Health Care Fund 6,297,900 sh (unchged)
Bill Frels 2,110,787 sh (-0.39%)
Mario Gabelli 73,189 sh (-1.92%)
Ken Fisher 267,380 sh (-13.63%)
Joel Greenblatt 17,326 sh (-36.01%)
David Dreman 27,489 sh (-44.61%)
Steven Cohen 19,952 sh (-92.71%)
» More
Q1 2014

STJ Guru Trades in Q1 2014

Pioneer Investments 79,135 sh (New)
Louis Moore Bacon 6,670 sh (New)
Steven Cohen 369,148 sh (+1750.18%)
Jeremy Grantham 804,577 sh (+258.54%)
David Dreman 47,202 sh (+71.71%)
Paul Tudor Jones 15,868 sh (+42.94%)
Andreas Halvorsen 1,901,750 sh (+27.91%)
Joel Greenblatt Sold Out
John Buckingham 109,649 sh (-0.46%)
Bill Frels 2,098,745 sh (-0.57%)
Ken Fisher 257,270 sh (-3.78%)
Vanguard Health Care Fund 5,844,300 sh (-7.2%)
James Barrow 2,917,285 sh (-7.44%)
John Rogers 1,404,552 sh (-12.46%)
John Hussman 300,000 sh (-14.29%)
Mario Gabelli 12,400 sh (-83.06%)
» More
Q2 2014

STJ Guru Trades in Q2 2014

Jim Simons 516,013 sh (New)
Joel Greenblatt 4,264 sh (New)
Mario Gabelli 37,400 sh (+201.61%)
Jeremy Grantham 1,736,038 sh (+115.77%)
Pioneer Investments 80,823 sh (+2.13%)
Ken Fisher 260,414 sh (+1.22%)
John Buckingham 110,899 sh (+1.14%)
James Barrow 2,940,885 sh (+0.81%)
Steven Cohen 186,200 sh (unchged)
Andreas Halvorsen Sold Out
Louis Moore Bacon Sold Out
Bill Frels 2,097,512 sh (-0.06%)
John Rogers 1,220,316 sh (-13.12%)
John Hussman 250,000 sh (-16.67%)
Vanguard Health Care Fund 4,301,100 sh (-26.41%)
David Dreman 31,736 sh (-32.77%)
Paul Tudor Jones 7,593 sh (-52.15%)
» More
» Details

Insider Trades

Latest Guru Trades with STJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Reduce -26.41%0.29%$61.64 - $70.46 $ 65.591%4301100
John Hussman 2014-06-30 Reduce -16.67%0.25%$61.64 - $70.46 $ 65.591%250000
David Dreman 2014-06-30 Reduce -32.77%0.08%$61.64 - $70.46 $ 65.591%31736
Mario Gabelli 2014-06-30 Add 201.61%0.01%$61.64 - $70.46 $ 65.591%37400
Joel Greenblatt 2014-06-30 New Buy$61.64 - $70.46 $ 65.591%4264
John Hussman 2014-03-31 Reduce -14.29%0.21%$59.4 - $68.48 $ 65.591%300000
David Dreman 2014-03-31 Add 71.71%0.1%$59.4 - $68.48 $ 65.591%47202
Joel Greenblatt 2014-03-31 Sold Out 0.03%$59.4 - $68.48 $ 65.591%0
Mario Gabelli 2014-03-31 Reduce -83.06%0.02%$59.4 - $68.48 $ 65.591%12400
John Hussman 2013-12-31 New Buy1.5%$54.58 - $62.74 $ 65.5913%350000
David Dreman 2013-12-31 Reduce -44.61%0.11%$54.58 - $62.74 $ 65.5913%27489
Joel Greenblatt 2013-12-31 Reduce -36.01%0.02%$54.58 - $62.74 $ 65.5913%17326
Vanguard Health Care Fund 2013-09-30 Reduce -12.98%0.16%$45.6 - $54.03 $ 65.5927%6297900
David Dreman 2013-09-30 Reduce -62.23%0.12%$45.6 - $54.03 $ 65.5927%49625
Joel Greenblatt 2013-09-30 Reduce -50.12%0.06%$45.6 - $54.03 $ 65.5927%27075
Ray Dalio 2013-09-30 Sold Out 0.04%$45.6 - $54.03 $ 65.5927%0
John Hussman 2013-09-30 Sold Out 0.01%$45.6 - $54.03 $ 65.5927%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about St Jude Medical Inc

Weekly 52-Week Highs Highlight: PPG, STJ, V, LLTC, LUV
According to GuruFocus list of 52-week highs, PPG Industries Inc., St Jude Medical Inc., Visa Inc., Linear Technology and Southwest Airlines Co. have all recently reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.10
STJ's P/E(ttm) is ranked higher than
88% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 78.90 vs. STJ: 21.10 )
STJ' s 10-Year P/E(ttm) Range
Min: 12.71   Max: 51.32
Current: 21.1

12.71
51.32
P/B 4.69
STJ's P/B is ranked higher than
50% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. STJ: 4.69 )
STJ' s 10-Year P/B Range
Min: 2.13   Max: 8.18
Current: 4.69

2.13
8.18
P/S 3.43
STJ's P/S is ranked higher than
57% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. STJ: 3.43 )
STJ' s 10-Year P/S Range
Min: 1.84   Max: 7.3
Current: 3.43

1.84
7.3
PFCF 20.50
STJ's PFCF is ranked higher than
91% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. STJ: 20.50 )
STJ' s 10-Year PFCF Range
Min: 9.89   Max: 41.61
Current: 20.5

9.89
41.61
EV-to-EBIT 20.11
STJ's EV-to-EBIT is ranked higher than
86% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 57.01 vs. STJ: 20.11 )
STJ' s 10-Year EV-to-EBIT Range
Min: 10   Max: 34.3
Current: 20.11

10
34.3
PEG 70.33
STJ's PEG is ranked higher than
87% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. STJ: 70.33 )
STJ' s 10-Year PEG Range
Min: 0.72   Max: 7.54
Current: 70.33

0.72
7.54
Shiller P/E 26.43
STJ's Shiller P/E is ranked higher than
87% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. STJ: 26.43 )
STJ' s 10-Year Shiller P/E Range
Min: 14.43   Max: 74.61
Current: 26.43

14.43
74.61
Current Ratio 2.31
STJ's Current Ratio is ranked higher than
63% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. STJ: 2.31 )
STJ' s 10-Year Current Ratio Range
Min: 1.15   Max: 4.53
Current: 2.31

1.15
4.53
Quick Ratio 1.87
STJ's Quick Ratio is ranked higher than
66% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. STJ: 1.87 )
STJ' s 10-Year Quick Ratio Range
Min: 0.9   Max: 3.54
Current: 1.87

0.9
3.54

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.59
STJ's Dividend Yield is ranked higher than
65% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 1.17 vs. STJ: 1.59 )
STJ' s 10-Year Dividend Yield Range
Min: 0.39   Max: 2.81
Current: 1.59

0.39
2.81
Dividend Payout 0.34
STJ's Dividend Payout is ranked higher than
86% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. STJ: 0.34 )
STJ' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.63
Current: 0.34

0.19
0.63
Yield on cost (5-Year) 1.60
STJ's Yield on cost (5-Year) is ranked higher than
57% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 1.23 vs. STJ: 1.60 )
STJ' s 10-Year Yield on cost (5-Year) Range
Min: 0.39   Max: 2.81
Current: 1.6

0.39
2.81
Share Buyback Rate 4.20
STJ's Share Buyback Rate is ranked higher than
97% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: -0.90 vs. STJ: 4.20 )
STJ' s 10-Year Share Buyback Rate Range
Min: 4.2   Max: -16.1
Current: 4.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.56
STJ's Price/DCF (Projected) is ranked higher than
90% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. STJ: 1.56 )
STJ' s 10-Year Price/DCF (Projected) Range
Min: 0.89   Max: 4.57
Current: 1.56

0.89
4.57
Price/Median PS Value 1.01
STJ's Price/Median PS Value is ranked higher than
79% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 1.15 vs. STJ: 1.01 )
STJ' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 2.13
Current: 1.01

0.56
2.13
Earnings Yield (Greenblatt) 5.00
STJ's Earnings Yield (Greenblatt) is ranked higher than
75% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. STJ: 5.00 )
STJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 10
Current: 5

2.9
10
Forward Rate of Return (Yacktman) 6.32
STJ's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. STJ: 6.32 )
STJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.7   Max: 24.3
Current: 6.32

6.7
24.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, EW » details
Traded in other countries:JUD.Germany
St. Jude Medical, Inc. was incorporated in Minnesota in 1976. The Company develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's four operating segments are Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation (NMD). Cardiac Rhythm Management engages in research, development and manufacture of products for cardiac arrhythmias, or irregular heartbeats. Its main products are tachycardia implantable cardioverter defibrillator systems (ICDs) and bradycardia pacemaker systems (pacemakers). The Cardiovascular division participates in segments of the vascular and structural heart markets. The main products of Cardiovascular are vascular products, which include vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories, and structural heart products, which include heart valve replacement and repair products and structural heart defect devices; Atrial Fibrillation is a condition in which the upper chambers of the heart (atria) beat rapidly and erratically, affecting the heart's ability to adequately pump blood to its lower chambers (ventricles) and subsequently to the rest of the body. Some of the complications caused by AF are increased risk of death or stroke, increased severity of stroke, increased hospitalizations, and reduced quality of life due to palpitations and other AF-related symptoms. Its products include electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. Its products are neurostimulation, which include spinal cord and deep brain stimulation devices. The Company markets and sells its products through both a direct sales force and independent distributors. The main geographic markets for its products are the United States, Europe, Japan and Asia Pacific. The Company's main competitors in this market are Medtronic, Inc. and Boston Scientific Corporation. These two competitors have invested substantial amounts in CRM research and development in a highly competitive market where rapid technological change is expected to continue, requiring the Company to invest heavily in R&D and effectively market its products. The Company's products, development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (FDCA), by comparable agencies in foreign countries and by other regulatory agencies and governing bodies.
» More Articles for STJ

Headlines

Articles On GuruFocus.com
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 
Weekly 52-Week Highs Highlight: PPG, STJ, V, LLTC, LUV Dec 23 2013 
Renaissance Technologies - Heavy Selling in Third Quarter, AAPL, MST, STJ, Others Nov 14 2013 
Weekly CFO Sells Highlight: TXN, AAPL, MAN, DHR, STJ, BAX Jul 29 2013 
comment on STJ Apr 21 2013 
Sarah Ketterer Returns 24 Pct in 2012, Her Top Q4 Buys Feb 25 2013 
Why Cooperman and Price Are Betting on Boston Scientific’s Turnaround Dec 31 2012 
My Best Healthcare Stock Picks For 2013 | Last Year’s Picks Gained 31.55% Dec 04 2012 
Weekly CEO Sells Highlight: Entegris, Honeywell International, St Jude Medical and Wesco Internation Nov 05 2012 
Six Stocks Will Benefit If Mitt Romeny Wins Oct 08 2012 


More From Other Websites
St. Jude Medical to Present at the Morgan Stanley Global Healthcare Conference Aug 28 2014
St. Jude Medical Settles FDA Warnings Letter for Texas Plant Aug 27 2014
St. Jude Medical Resolves FDA Warning Letter for Plano Facility Aug 26 2014
Why St. Jude Medical Has Become a Must-Own Medical Device Stock Aug 26 2014
St. Jude Medical Completes Acquiring Pain Solutions Maker Aug 13 2014
Volcano Reports Second Quarter Results Aug 07 2014
St. Jude Medical Completes Acquisition of NeuroTherm Aug 07 2014
ST JUDE MEDICAL INC Financials Aug 06 2014
CardioMEMS Heart Failure Monitoring System Receives Approval from CMS for New Technology Add-On... Aug 05 2014
Wall Street Transcript Interview with Mark D. Perrin, the CEO of InVivo Therapeutics Corporation... Aug 01 2014
Obamacare Becomes a Long-Term Tailwind for Creating Value for Senior Housing REITs: A Wall Street... Aug 01 2014
ST JUDE MEDICAL INC Files SEC form 10-Q, Quarterly Report Jul 30 2014
St. Jude Medical Announces Third Quarter Dividend Jul 29 2014
St. Jude Medical Gets CE Mark for FlexAbility Catheter Jul 24 2014
St. Jude announces FlexAbility Ablation Catheter CE Mark approval, first use Jul 22 2014
St. Jude Medical Announces CE Mark Approval and First Use of the FlexAbility Ablation Catheter Jul 22 2014
Red Flags from Weekly Charts Jul 21 2014
Abbott, St. Jude Top Views, But Stocks Under Pressure Jul 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK